Document is current
Any future updates will be listed below
-
Authors
Volzone, Francesco https://orcid.org/0000-0001-6509-0578
Becchimanzi, Cristina https://orcid.org/0000-0003-1299-6573
Crisci, Stefania
De Chiara, Annarosaria
Porto, Annamaria
Caronna, Antonietta
Cuccaro, Annarosa
Sarno, Sabrina https://orcid.org/0000-0002-8190-361X
Mallardo, Domenico https://orcid.org/0000-0002-1081-5313
Cagini, Lucio
De Filippi, Rosaria https://orcid.org/0000-0001-7899-3071
Pinto, Antonio https://orcid.org/0000-0002-9425-9026
-
Funding
Funding for this research was provided by:
This work was supported by the Italian Ministry of Health, Rome, Italy. (Ricerca Corrente IRCCS Funds, Progetto L2 /11)
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 3 September 2024
First Online: 12 September 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and the Institutional Review Boards-approved LYMRO-22 study (20/22 OSS; date of approval 27 July 2022, Istituto Pascale, Italy). Patients enrolled into the LYMRO-22 allow the use of anonymized registered clinical data for scientific purposes.
: Informed consent has been obtained from the patient for clinical. data collection, elaboration and publication of the present report.
: FV declares honoraria from Hoffmann-La Roche AG irrelevant to the present research; AP declares honoraria from Hoffmann-La Roche AG, Incyte, Merck Sharp and Dohme, Bristol-Meyers Squibb and Ely-Lilly all irrelevant to the present research. AnC declares honoraria from Takeda, irrelevant to the present research. All the other authors declare no conflict of interest.
: N/A.
